Opinion

Video

Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL

Panelists discuss how distinct safety profiles among Bruton tyrosine kinase (BTK) inhibitors—including variations in cardiovascular effects, bleeding risk, infection susceptibility, and other adverse events—guide personalized treatment decisions in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) based on individual comorbidities and risk factors.

Related Videos
4 experts are featured in this series.
1 expert in this video
5 experts are featured in this series
1 expert in this video
5 experts are featured in this series
4 experts are featured in this series.
Raj Chovatiya, MD, PhD, MSCI.
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo